CD28 and neoplasm: When testing PD1-CD3ζ/DAP10 CAR-T cells in a mouse model of lymphoma, Lynch et al. saw significantly enhanced persistence compared to a CD28 co-stimulated CAR, leading to long-term tumor-free survival [192].